Journal of Clinical Densitometry
Volume 10, Issue 3 , Pages 259-265 , July 2007

The Correction of BMD Measurements for Bone Strontium Content

  • Glen M. Blake

      Affiliations

    • Corresponding Author InformationAddress correspondence to: G.M. Blake, PhD, Department of Nuclear Medicine, King's College London School of Medicine, Guy's Hospital, St Thomas Street, London SE1 9RT, United Kingdom.
    • ,
  • Ignac Fogelman

Received 14 February 2007 ,Accepted 29 March 2007.

References 

  1. Blake GM, Lewiecki EM, Kendler DL, Fogelman I. 2007 A review of strontium ranelate and its effect on DXA scans. J Clin Densitom 10:113–119.
  2. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459–468
  3. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90:2816–2822
  4. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535–1541
  5. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised clinical trial. JAMA. 1999;282:637–645
  6. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. JAMA. 1999;282:1344–1352
  7. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–1249
  8. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis—a 2-year randomised placebo controlled trial. J Clin Endocrinol Metab. 2002;87:2060–2066
  9. Reginster JY, Deroisy R, Dougados M, et al. Prevention of early postmenopausal bone loss by strontium ranelate: the randomised, two-year, double-masked, dose ranging, placebo-controlled PREVOS trial. Osteoporos Int. 2002;13:925–931
  10. Arlot ME, Delmas P, Burt-Pichat B, Roux JP, Portero N, Meunier PJ. The effects of strontium ranelate on bone remodelling and bone safety assessed by histomorphometry in patients with postmenopausal osteoporosis. J Bone Miner Res. 2005;20(Suppl 1):S22–S23
  11. Boivin G, Farley D, Simi C, Meunier PJ. Bone strontium distribution and degree of mineralization of bone in postmenopausal osteoporotic women treated with strontium ranelate for 2 and 3 years. Osteoporos Int. 2006;17(Suppl 2):S210
  12. Goldman M, Della Rosa RJ. Studies of the dynamics of strontium metabolism under conditions of continual ingestion to maturity. In:  Lenihan JMA,  Loutit JF,  Martin JH editor. Strontium Metabolism. New York: Academic Press; 1967;p. 181–194
  13. Boivin G, Deloffre P, Perrat B, et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S12911) administration. J Bone Miner Res. 1996;11:1302–1311
  14. Dahl SG, Allain P, Marie PJ, et al. Incorporation and distribution of strontium in bone. Bone. 2001;28:446–453
  15. Farlay D, Boivin G, Pranczer G, Alande A, Meunier PJ. Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone. J Bone Miner Res. 2005;20:1569–1578
  16. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437–1443
  17. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997;350:550–555
  18. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441
  19. Fogelman I, Blake GM. Strontium ranelate for the treatment of osteoporosis. BMJ. 2005;330:1400–1401
  20. Blake GM, Fogelman I. Theoretical model for the interpretation of BMD scans in patients stopping strontium ranelate treatment. J Bone Miner Res. 2006;21:1417–1424
  21. Pors Nielsen S, Slosman D, Sorensen OH, et al. Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry. J Clin Densitom. 1999;2:371–379
  22. Ho CP, Kim RW, Schaffler MB, Sartoris DJ. Accuracy of dual-energy radiographic absorptiometry of the lumbar spine: a cadaver study. Radiology. 1990;176:171–173
  23. SPC . Summary of product characteristics. Protelos (Strontium ranelate 2g granules). Neuilly-sur-Seine, France: Les Laboratories Servier; 2004;
  24. Blake GM, Fogelman I. The effect of bone strontium on BMD measurements. J Clin Densitom. 2007;10:34–38
  25. Reginster JY, Deroisy R, Juspin I. Strontium ranelate: a new paradigm in the treatment of osteoporosis. Drugs Today. 2003;39:89–101
  26. Marie PJ. Strontium ranelate: a novel mode of action optimizing bone formation and bone resorption. Osteoporos Int. 2005;16(Suppl 1):S7–S10
  27. Ammann P, Shen V, Robin B, Mauras Y, Bonjour J-P, Rizzoli R. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res. 2004;19:2012–2020
  28. Jiang Y, Genant H, Zhao J. Effect of strontium ranelate on 3D cortical and trabecular microstructure in postmenopausal osteoporosis in multicentre, double-blind, and placebo controlled studies. J Bone Miner Res. 2006;21(Suppl 1):S44

PII: S1094-6950(07)00138-2

doi: 10.1016/j.jocd.2007.03.102

Journal of Clinical Densitometry
Volume 10, Issue 3 , Pages 259-265 , July 2007

Article Tools

* Image Usage & Resolution